Biological: Clinical Trials

5 trials of Biological, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 not yet recruiting, 1 recruiting, 1 unknown. 5 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Terminated 2, Not yet recruiting 1, Recruiting 1, Unknown 1
Phase 22Terminated 1, Unknown 1

Follow Biological: new trials by email Literature Review of Biological trials Research Report on Biological

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A
Gene therapy, Biological - Hemophilia A
Phase 1Not yet recruitingExpression Therapeutics, LLC72024-09-012024-02-20
Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors
Biological - Refractory/Relapse Neuroblastoma, Pediatric Solid Tumors
Phase 1RecruitingKyushu University612022-10-262026-08-07
Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC
Biological - Cell Therapy, NSCLC
Phase 1 / Phase 2TerminatedGAIA BioMedicine Inc.222021-12-012026-09-03
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
NZV930, PDR001, NIR178 - Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC)
Phase 1TerminatedNovartis Pharmaceuticals1272018-07-182024-12-13
Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy
Biological - Treatment of Type I Diabetes Mellitus.
Phase 1 / Phase 2UnknownDiaVacs, Inc.902013-10-012013-10-23

Conditions studied

Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Hemophilia A (1)  ·  Ovarian Neoplasms (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

DiaVacs, Inc. (1)  ·  Expression Therapeutics, LLC (1)  ·  GAIA BioMedicine Inc. (1)  ·  Kyushu University (1)  ·  Novartis Pharmaceuticals (1)

Countries

Japan (3)  ·  United States (2)  ·  Australia (1)  ·  Canada (1)  ·  Singapore (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Yoshikazu Yonemitsu, MD, PhD (1)

NIH funding

2018 (1)